EA200001112A1 - Безводные и моногидратные формы n- (3-этинилфениламино)-6,7- бис (2-метоксиэтокси)-4-хиназолинамина мезилата - Google Patents

Безводные и моногидратные формы n- (3-этинилфениламино)-6,7- бис (2-метоксиэтокси)-4-хиназолинамина мезилата

Info

Publication number
EA200001112A1
EA200001112A1 EA200001112A EA200001112A EA200001112A1 EA 200001112 A1 EA200001112 A1 EA 200001112A1 EA 200001112 A EA200001112 A EA 200001112A EA 200001112 A EA200001112 A EA 200001112A EA 200001112 A1 EA200001112 A1 EA 200001112A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methoxyethoxy
bis
anhydrous
mezilate
hinazolinamine
Prior art date
Application number
EA200001112A
Other languages
English (en)
Other versions
EA002836B1 (ru
Inventor
Дуглас Джон Мелдрум Аллен
Тимоти Норрис
Джеффри Уилльям Рэггон
Динос Пол Сантафианос
Рави Мисор Шэнкер
Original Assignee
Оси Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Оси Фармасьютикалз, Инк. filed Critical Оси Фармасьютикалз, Инк.
Publication of EA200001112A1 publication Critical patent/EA200001112A1/ru
Publication of EA002836B1 publication Critical patent/EA002836B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Abstract

Данное изобретение относится к безводным и гидратным формам N-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина мезилата. Изобретение также относится к фармацевтическим композициям, содержащим N-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина мезилат, и способам лечения высокопролиферативных нарушений, таких как рак, введением N-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина мезилата.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200001112A 1998-04-29 1999-04-08 Безводные и моногидратные формы n-(3-этинилфениламино)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина мезилата EA002836B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8344198P 1998-04-29 1998-04-29
PCT/IB1999/000612 WO1999055683A1 (en) 1998-04-29 1999-04-08 N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate

Publications (2)

Publication Number Publication Date
EA200001112A1 true EA200001112A1 (ru) 2001-04-23
EA002836B1 EA002836B1 (ru) 2002-10-31

Family

ID=22178359

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200001112A EA002836B1 (ru) 1998-04-29 1999-04-08 Безводные и моногидратные формы n-(3-этинилфениламино)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина мезилата

Country Status (42)

Country Link
EP (1) EP1076652B1 (ru)
JP (1) JP4652569B2 (ru)
KR (1) KR100668412B1 (ru)
CN (2) CN1298396A (ru)
AP (1) AP1252A (ru)
AR (1) AR018201A1 (ru)
AT (1) ATE295839T1 (ru)
AU (1) AU759691C (ru)
BR (1) BR9910025A (ru)
CA (1) CA2330447C (ru)
CO (1) CO5060467A1 (ru)
CZ (1) CZ298230B6 (ru)
DE (1) DE69925366T2 (ru)
DZ (1) DZ2777A1 (ru)
EA (1) EA002836B1 (ru)
EG (1) EG24000A (ru)
ES (1) ES2238825T3 (ru)
GT (1) GT199900063A (ru)
HK (1) HK1037180A1 (ru)
HN (1) HN1999000057A (ru)
HU (1) HU227569B1 (ru)
ID (1) ID27198A (ru)
IL (1) IL139172A0 (ru)
MA (1) MA26624A1 (ru)
ME (1) MEP42008A (ru)
MX (1) MXPA00010610A (ru)
MY (1) MY136033A (ru)
NO (1) NO317301B1 (ru)
NZ (1) NZ508154A (ru)
OA (1) OA11769A (ru)
PA (1) PA8471001A1 (ru)
PE (1) PE20000441A1 (ru)
PL (1) PL196940B1 (ru)
RS (1) RS50081B (ru)
SA (1) SA99200216B1 (ru)
TN (1) TNSN99079A1 (ru)
TR (1) TR200003166T2 (ru)
TW (1) TWI248437B (ru)
UA (1) UA60363C2 (ru)
UY (1) UY26099A1 (ru)
WO (1) WO1999055683A1 (ru)
ZA (1) ZA992972B (ru)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
YU13200A (sh) 1999-03-31 2002-10-18 Pfizer Products Inc. Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
UA74803C2 (ru) * 1999-11-11 2006-02-15 Осі Фармасьютікалз, Інк. Стойкий полиморф гидрохлорида n-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина, способ его получения (варианты) и фармацевтическое применение
UA73993C2 (ru) * 2000-06-06 2005-10-17 Астразенека Аб Хиназолиновые производные для лечения опухолей и фармацевтическая композиция
AU2002350105A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel quinazolines and uses thereof
US7078409B2 (en) 2002-03-28 2006-07-18 Beta Pharma, Inc. Fused quinazoline derivatives useful as tyrosine kinase inhibitors
GB0223854D0 (en) * 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
US7148231B2 (en) * 2003-02-17 2006-12-12 Hoffmann-La Roche Inc. [6,7-Bis(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)amine hydrochloride polymorph
MXPA05012939A (es) 2003-05-30 2006-05-17 Astrazeneca Uk Ltd Procedimiento.
BRPI0411126A (pt) 2003-06-10 2006-07-18 Hoffmann La Roche derivados de 1,3,4-triaza-fenaleno e 1,3,4,6-tetraazafenaleno
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
CA2565721C (en) 2004-05-06 2015-10-06 Bioresponse, L.L.C. Diindolymethane formulations for the treatment of leiomyomas
ATE497762T1 (de) 2004-12-30 2011-02-15 Bioresponse Llc Verwendung von diindolylmethan-verwandten indolen zur behandlung und prävention von erkrankungen im zusammenhang mit dem respiratory syncytial virus
CA2659307A1 (en) 2006-07-28 2008-01-31 Synthon B.V. Crystalline erlotinib
WO2008057253A2 (en) 2006-10-27 2008-05-15 Bioresponse, L.L.C. Anti-parasitic methods and compositions utilizing diindolylmethane-related indoles
AU2008235274B2 (en) * 2007-04-04 2013-04-18 Cipla Limited Process for preparation of erlotinib and its pharmaceutically acceptable salts
ES2492645T3 (es) 2007-07-11 2014-09-10 Hetero Drugs Limited Un procedimiento mejorado para la preparación de hidrocloruro de erlotinib
WO2009024989A2 (en) 2007-08-17 2009-02-26 Hetero Drugs Limited A novel hydrated form of erlotinib free base and a process for preparation of erlotinib hydrochloride polymorph form a substantially free of polymorph form b
KR101132937B1 (ko) * 2008-10-01 2012-04-06 주식회사종근당 Ｎ-(3-에티닐페닐)-6,7-비스(2-메톡시에톡시)-4-퀴나졸린아민 납실레이트 염
US8440823B2 (en) 2009-03-26 2013-05-14 Ranbaxy Laboratories Limited Process for the preparation of erlotinib or its pharmaceutically acceptable salts thereof
WO2011068404A2 (en) 2009-12-02 2011-06-09 Ultimorphix Technologies B.V. Administration of n-(3-ethynylphenylamino)-6,7-bis(2- methoxyethoxy)-4-quinazolinamine mesylate salt by inhalation
DE202010006543U1 (de) 2010-05-07 2010-09-09 Ratiopharm Gmbh Erlotinibresinat
HU230483B1 (hu) 2011-10-10 2016-07-28 Egis Gyógyszergyár Nyrt. Erlotinib sók
WO2014037961A1 (en) 2012-09-04 2014-03-13 Shilpa Medicare Limited Crystalline erlotinib hydrochloride process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ243082A (en) * 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
JP2994165B2 (ja) * 1992-06-26 1999-12-27 ゼネカ・リミテッド キナゾリン誘導体、その製造法および該キナゾリン誘導体を含有する抗癌作用を得るための医薬調剤
GB9323290D0 (en) * 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
ES2332984T3 (es) * 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
US5747498A (en) * 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines

Also Published As

Publication number Publication date
DE69925366T2 (de) 2006-03-09
DZ2777A1 (fr) 2003-12-01
NZ508154A (en) 2003-07-25
UY26099A1 (es) 2001-12-28
YU66100A (sh) 2003-07-07
KR100668412B1 (ko) 2007-01-12
MA26624A1 (fr) 2004-12-20
NO317301B1 (no) 2004-10-04
NO20005453D0 (no) 2000-10-27
TNSN99079A1 (fr) 2005-11-10
ZA992972B (en) 2000-10-30
ATE295839T1 (de) 2005-06-15
MY136033A (en) 2008-07-31
IL139172A0 (en) 2001-11-25
SA99200216B1 (ar) 2006-06-04
PL343766A1 (en) 2001-09-10
ES2238825T3 (es) 2005-09-01
PL196940B1 (pl) 2008-02-29
AU759691B2 (en) 2003-04-17
KR20010078710A (ko) 2001-08-21
AP1252A (en) 2004-02-25
PA8471001A1 (es) 2000-09-29
JP4652569B2 (ja) 2011-03-16
WO1999055683A1 (en) 1999-11-04
CO5060467A1 (es) 2001-07-30
AR018201A1 (es) 2001-10-31
AU759691C (en) 2004-04-29
PE20000441A1 (es) 2000-05-23
CZ20003974A3 (en) 2001-05-16
MEP42008A (en) 2011-02-10
GT199900063A (es) 2000-10-20
CN101219999A (zh) 2008-07-16
BR9910025A (pt) 2000-12-26
HUP0101818A3 (en) 2002-05-28
EP1076652B1 (en) 2005-05-18
RS50081B (sr) 2009-01-22
UA60363C2 (ru) 2003-10-15
DE69925366D1 (de) 2005-06-23
TR200003166T2 (tr) 2001-02-21
AU2850999A (en) 1999-11-16
CZ298230B6 (cs) 2007-08-01
HU227569B1 (en) 2011-08-29
JP2002513009A (ja) 2002-05-08
HK1037180A1 (en) 2002-02-01
NO20005453L (no) 2000-12-20
MXPA00010610A (es) 2002-07-02
TWI248437B (en) 2006-02-01
HN1999000057A (es) 1999-09-29
EG24000A (en) 2008-03-19
HUP0101818A1 (hu) 2002-03-28
OA11769A (en) 2005-07-25
CN1298396A (zh) 2001-06-06
ID27198A (id) 2001-03-08
EA002836B1 (ru) 2002-10-31
AP9901523A0 (en) 1999-06-30
CA2330447C (en) 2009-06-30
EP1076652A1 (en) 2001-02-21
CA2330447A1 (en) 1999-11-04

Similar Documents

Publication Publication Date Title
EA200001112A1 (ru) Безводные и моногидратные формы n- (3-этинилфениламино)-6,7- бис (2-метоксиэтокси)-4-хиназолинамина мезилата
EA200300788A1 (ru) Производные замещенных алкиламинов и их применение
EA200200546A1 (ru) Устойчивый полиморф гидрохлорида n-(3-этинилфенил)-6,7-бис(2-метоксиэтокси)-4-хиназолинамина, способы его получения и фармацевтические применения
EA200400006A1 (ru) Бензоилсульфонамиды и сульфонилбензамидины для применения в качестве противоопухолевых агентов
EA200100589A1 (ru) Азабициклоалканы как модуляторы ccr5
BR0215360A (pt) Derivados de indolina úteis como inibidores de proteìna quinase
EA200500169A1 (ru) Замещенные производные 1,3-дифенилпроп-2-ен-1-она, получение и применение
EA200500488A1 (ru) Фармацевтические составы модафинила
DE60142921D1 (de) Azaphenanthridone-derivate und deren verwendung als parp-inhibitoren
DE60118003D1 (de) Harnstoffderivate und ihre verwendung
DE69824029D1 (de) Bicyclische kinase inhibitoren
EA200101177A1 (ru) Производные индола в качестве антагонистов прогестерона
EA200200058A1 (ru) Пиримидин-2,4,6-трионовые ингибиторы металлопротеиназ
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
NO20030845D0 (no) Utvalgte fusjonerte pyrrolokarbazoler
ATE266675T1 (de) Troponin untereinheiten und fragmente zur verwendung als inhibitoren der angiogenese
EA200500849A1 (ru) Новые соединения лапахона и способы их применения
UY28519A1 (es) Derivados de quinazolina
ATE338047T1 (de) Stickstoffbasierte camptothecin-derivate
EA200000519A1 (ru) 2-АРИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
DE60213802D1 (de) Cak inhibitoren und deren verwendungen
EA200000520A1 (ru) 2-АРИЛ-3-АРОИЛБЕНЗО[b]ТИОФЕНЫ, ПОЛЕЗНЫЕ ДЛЯ ЛЕЧЕНИЯ СИНДРОМА ЭСТРОГЕННОЙ НЕДОСТАТОЧНОСТИ
BR0016638B1 (pt) compostos anÁlogos de homopiperidilbenzimidazàis substituÍdos como relaxantes féndicos, processo para preparar os mesmos, composiÇço farmacÊutica e processo para preparÁ-la.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU